← Back to Search

Other

ABBV-552 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 30 days
Awards & highlights

Summary

This trial aims to study how the body processes and eliminates a drug called ABBV-552 in healthy men after they take a single dose by mouth.

Who is the study for?
This trial is for healthy male volunteers. To participate, they must be in good general health at the time of screening.Check my eligibility
What is being tested?
The study is testing ABBV-552 by giving a single oral dose to participants. It aims to assess how the body processes this drug and its safety profile.See study design
What are the potential side effects?
Since this is an early-stage trial focusing on pharmacokinetics, specific side effects are not listed but generally may include reactions at the site of administration, nausea, headache or other common drug-related side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Amount of ABBV-552 excreted in the feces over the sampling period (Aef)
Amount of ABBV-552 excreted in the urine over the sampling period (Aeu)
Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-552
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABBV-552Experimental Treatment1 Intervention
Participants will receive ABBV-552 on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-552
2023
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
983 Previous Clinical Trials
509,353 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
414 Previous Clinical Trials
151,884 Total Patients Enrolled
~5 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top